EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence

Raffaele Pellegrino iD, Giuseppe Imperio, Ilaria De Costanzo, Michele Izzo, Fabio Landa, Assunta Tambaro, Antonietta Gerarda Gravina iD, Alessandro Federico

Pharmaceuticals · 23.02.2025 · 18 (3) · 308

DOI: 10.3390/ph18030308 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 23.02.2025. Verfasst von Raffaele Pellegrino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is an inflammatory bowel disease in which one-quarter of patients are at risk of developing a severe form of the disease known as acute severe UC (ASUC). This condition exposes patients to serious complications, including toxic megacolon, surgical intervention, and even death. The current therapeutic strategy relies on time-dependent, multi-step algorithms that integrate systemic corticosteroids, calcineurin inhibitors, and biologic agents (specifically infliximab) as medical therapy aimed at avoiding colectomy. Despite this approach, a significant proportion of patients fail to respond to either corticosteroids or infliximab and may require alternative therapeutic options if there is no urgent surgical necessity. These alternatives include other biologics or emerging small molecules, although the evidence supporting these treatments remains extremely low, even considering their well-documented and promising efficacy and safety in moderate-to-severe UC. Conversely, it is necessary to investigate whether infliximab can be effectively replaced or surpassed by other approved biological agents and small molecules as first-line therapy after steroid resistance. This review aims to summarise the available evidence on small molecules, specifically Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators.

Schlagwörter

Stichwörter der Autor:innen

acute severe ulcerative colitisbiologicsetrasimodfilgotinibozanimodsequencingsmall moleculestofacitinibulcerative colitisupadacitinib

Autor:innen und Institutionen

  • Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy.

ORCID-Profile: Raffaele Pellegrino, Antonietta Gerarda Gravina

Zitieren

APA

Pellegrino, R., Imperio, G., De Costanzo, I., Izzo, M., Landa, F., Tambaro, A., Gravina, A. G., & Federico, A. (2025). Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence. Pharmaceuticals, 18(3), 308. https://doi.org/10.3390/ph18030308

Vancouver

Pellegrino R, Imperio G, De Costanzo I, Izzo M, Landa F, Tambaro A, et al. Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence. Pharmaceuticals. 2025;18(3):308. doi:10.3390/ph18030308

BibTeX
@article{Pellegrino2025,
  author = {Pellegrino, Raffaele and Imperio, Giuseppe and De Costanzo, Ilaria and Izzo, Michele and Landa, Fabio and Tambaro, Assunta and Gravina, Antonietta Gerarda and Federico, Alessandro},
  title = {Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {308},
  doi = {10.3390/ph18030308}
}
Kostenlos starten →